Nevertheless, this therapy is effective only in a subset of SLE patients,5, 6 suggesting a potential BAFF‐mediated subset of SLE, and a significant unmet need for tools to stratify patients in order to define who may benefit from such therapy. This evidence concerns the gene TNFSF13B and systemic lupus erythematosus.